Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Characterisation of peripheral...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Export Ready — 
Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis

Characterisation of peripheral blood mononuclear cells in patients with combination ipilimumab and nivolumab therapy-related colitis

Bibliographic Details
Main Authors: Sasson, SC, Zaunders, J, Nahar, K, Munier, C, Read, SA, Ahlensteil, G, Palendira, U, Scolyer, RA, Carlino, M, Long, GV, Menzies, AM, Kelleher, AD
Format: Conference item
Language:English
Published: Elsevier 2019
  • Holdings
  • Description
  • Similar Items
  • Staff View

Similar Items

  • Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis
    by: Sasson, SC, et al.
    Published: (2020)
  • Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis
    by: Sasson, SC, et al.
    Published: (2019)
  • Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
    by: Serigne Lo, et al.
    Published: (2020-10-01)
  • Ipilimumab- and Nivolumab-Induced Colitis Causing Severe Hypokalemia and QTc Prolongation
    by: David Anson, et al.
    Published: (2019-01-01)
  • A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome
    by: Ian M. Bouligny, et al.
    Published: (2025-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs